Pathological and clinical impact of neoadjuvant chemoradiotherapy using full‐dose gemcitabine and concurrent radiation for resectable pancreatic cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1868-6982|20|2|197-205

ISSN： 1868-6974

Source： JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol.20, Iss.2, 2013-02, pp. : 197-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemoradiotherapy in Patients with Pancreatic Carcinoma: Phase-I Study with a Fixed Radiation Dose and Escalating Doses of Weekly Gemcitabine

By  

Pancreatology, Vol. 6, Iss. 1-2, 2006-04 ,pp. : 109-116

Karger

Access to resources Recommend Favorite

Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer

By  

Pancreatology, Vol. 10, Iss. 1, 2010-03 ,pp. : 60-65

Karger

Access to resources Recommend Favorite

Complete clinical response to neoadjuvant chemoradiotherapy for rectal cancer: an Australasian perspective

By  

ANZ JOURNAL OF SURGERY, Vol. 85, Iss. 3, 2015-03 ,pp. : 103-104

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review

By  

COLORECTAL DISEASE, Vol. 17, Iss. 10, 2015-10 ,pp. : 849-861

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 648-655

Karger

Access to resources Recommend Favorite